Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

SCO-940/CT-G32

Stage Preclinical

Sponsor SCOHIA PHARMA, Inc.

Mechanism quadruple agonist

Sources

company_release, as of 2026-11-04

https://www.scohia.com/eng/sys/news/261104_sco940_tideseurope_en/

SCOHIA PHARMA, Inc. announced today that the first preclinical study results for its next-generation obesity drug candidate SCO-940/CT-G32 were presented at TIDES Europe. Development is on track for an IND submission to the U.S. FDA in February next year and first patient dosing in the second quarter by our strategic partner, Celltrion Inc.

SCOHIA PHARMA news dated 2026.11.04

Studies

No trial is in this file.

Catalyst IND submission. Development is on track for an IND submission to the U.S. FDA in February next year.